SGMOQ — Sangamo Therapeutics Share News
0.000.00%
Last trade - 00:00- $18.64m
- -$8.94m
- $39.55m
Sangamo Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Sangamo Therapeutics Q3 Operating Income USD 10.631 Million
Sangamo Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview
Sangamo Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Freeport-McMoRan, A.O. Smith, Genuine Parts
U.S. STOCKS ON THE MOVE-Lockheed Martin, General Motors, Philip Morris International
Sangamo surges as FDA says no additional study required for gene therapy accelerated approval
Brief: Sangamo Therapeutics Announces Alignment With FDA On Accelerated Approval Pathway For St-920 In Fabry Disease With BLA Submission Expected In 2025
Sangamo Therapeutics rises on FDA feedback for gene therapy study
US FDA approves Pfizer's drug for rare bleeding disorder
Sangamo Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Sangamo Therapeutics Q2 EPS USD -0.18 Vs. IBES Estimate USD -0.15
U.S. STOCKS ON THE MOVE-IDEXX, Amgen, Airbnb
Sangamo Therapeutics rises on licensing agreement with Genentech
Brief: Sangamo Therapeutics Announces Global Epigenetic Regulation And Capsid Delivery License Agreement With Genentech
Sangamo Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tesla, Lamb Weston, Blackstone Mortgage Trust
U.S. STOCKS ON THE MOVE-FTAI Aviation, Check Point, Sage Therapeutics
Sangamo rises on bleeding disorder gene therapy trial data